Research programme: adipose mesenchymal stem cell derived therapeutic factor concentrates - NeuroFx/Cytovance Biologics

Drug Profile

Research programme: adipose mesenchymal stem cell derived therapeutic factor concentrates - NeuroFx/Cytovance Biologics

Alternative Names: NFx-101

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator NeuroFx
  • Developer Cytovance Biologics; NeuroFx
  • Class Stem cell factors
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Macrophage inhibitors; Neurogenesis stimulants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain injuries; Neurological disorders

Most Recent Events

  • 12 Aug 2015 Preclinical trials in Neurological disorders in USA (Parenteral) prior to August 2015
  • 12 Aug 2015 Preclinical trials in Brain injuries in USA (Parenteral) prior to August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top